Zoetis stock raises profit outlook as pet-care pressure persists

Published on 11/10/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zoetis stock remains in focus after mixed third-quarter results and a higher profit outlook. Portfolio pressure still weighs on growth.

Zoetis Balances Growth And Pressure

Third-quarter revenue fell 1 percent to 2.391 billion US dollars, while adjusted diluted EPS rose 3 percent to 1.75 US dollars.
Zoetis raised its full-year adjusted diluted EPS outlook to 6.25 to 6.35 US dollars.
Companion animal demand remained under pressure, while livestock and diagnostics supported the portfolio.

ZTS, US98978V1035, Illustration mit AI erstellt.

Zoetis reported mixed third-quarter results on Thursday, November 5, 2026, as revenue slipped while adjusted earnings per share increased and management raised its full-year profit outlook. The company said its performance was in line with expectations in its November 5 results release.

Guidance Improves Despite Pressure

Third-quarter revenue was 2.391 billion US dollars, down 1 percent from a year earlier. Reported net income declined 18 percent to 591 million US dollars, while adjusted net income fell 5 percent to 720 million US dollars.

Adjusted diluted EPS rose 3 percent to 1.75 US dollars. The adjusted figure excludes a net impact of 129 million US dollars from purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.

Zoetis narrowed its full-year revenue guidance to 9.220 billion to 9.320 billion US dollars and raised adjusted net income guidance to 2.600 billion to 2.640 billion US dollars. Adjusted diluted EPS guidance increased to 6.25 to 6.35 US dollars.

Portfolio Mix Remains Decisive

U.S. revenue declined 6 percent, with companion animal revenue down 8 percent as price sensitivity, dermatology competition and generic competition weighed on demand. U.S. livestock revenue increased 5 percent.

International revenue increased 4 percent. International livestock revenue grew 8 percent, while international companion animal revenue rose 1 percent on a reported basis. The results leave the portfolio mix and product launches central to the earnings outlook.

Pipeline Adds Near-Term Milestones

Zoetis said select approvals previously expected in 2027 are now anticipated in the fourth quarter of 2026. The company expects Convenia RTU for Dogs to become available to veterinarians in the first quarter of 2027 after its U.S. approval in October.

Zoetis stock traded at 73.95 euros on Lang & Schwarz at 13:32 CET on Tuesday, November 10, 2026.